NCT05968417Recruiting
Myeloma Novel Drug Discovery Ver 1.2
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
Source: ClinicalTrials.gov · Last updated 3 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 21 Jul 2023
- Start date
- 22 Jul 2020
- Primary completion date
- 28 Feb 2033
- Lead sponsor
- Institute of Cancer Research, United Kingdom
- Diseases
- Multiple myeloma
- NCT number
- NCT05968417
What you commit to
- Study type: Observational
- Planned participants: 250
- From 22 Jul 2020 to the primary completion date, 28 Feb 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Other
- Participants unable to provide consent
Who the study is looking for
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden NHS Foundation Trust Coordinator of this site? Confirm its status | Sutton | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.